Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States
Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham H, Zhou Y, Li J, Zhang X, Xu H, Taner C, Yang L, Tao C. Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Alimentary Pharmacology & Therapeutics 2021, 54: 481-492. PMID: 34224163, DOI: 10.1111/apt.16490.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsCarcinoma, HepatocellularHumansLiver CirrhosisLiver NeoplasmsRetrospective StudiesUnited StatesConceptsRisk of HCCBeta-blocker groupHepatocellular carcinomaCirrhotic patientsCerner Health Facts databaseCox proportional hazards regressionCumulative HCC incidenceRetrospective cohort studyHealth Facts databasePopulation-based studyProportional hazards regressionKaplan-Meier estimatesEligible patientsCohort studyHCC incidenceFinal cohortHazards regressionHCC riskLower riskPropensity scorePatientsCarvedilolRiskFacts databaseGroup